Seladelpar

CHEMBL230158 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

444.5 g/mol

LogP

5.2

Phase

4

Seladelpar is a selective peroxisome proliferator-activated receptor delta (PPAR-delta) agonist under investigation for the treatment of primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH). By activating PPAR-delta in hepatocytes and cholangiocytes, it modulates bile acid synthesis, reduces hepatic inflammation, and improves metabolic parameters. Clinical trials have demonstrated reductions in alkaline phosphatase and pruritus in PBC patients.

Masse moléculaire

444,5000 g/mol

LogP

5,20

TPSA

90,30 Å²

Règle des 5 de Lipinski

Conforme

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCO[C@H](COc1ccc(C(F)(F)F)cc1)CSc1ccc(OCC(=O)O)c(C)c1

InChI

InChI=1S/C21H23F3O5S/c1-3-27-17(11-28-16-6-4-15(5-7-16)21(22,23)24)13-30-18-8-9-19(14(2)10-18)29-12-20(25)26/h4-10,17H,3,11-13H2,1-2H3,(H,25,26)/t17-/m1/s1

Molecular Formula

C21H23F3O5S

HBD / HBA

1 / 9

Liaisons Rotatives

11

Atomes Lourds

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

Seladelpar is a selective peroxisome proliferator-activated receptor delta (PPAR-delta) agonist under investigation for the treatment of primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH). By activating PPAR-delta in hepatocytes and cholangiocytes, it modulates bile acid synthesis, reduces hepatic inflammation, and improves metabolic parameters. Clinical trials have demonstrated reductions in alkaline phosphatase and pruritus in PBC patients.

Yes, Seladelpar is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL230158. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 11236126. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Seladelpar sur PillFYI

Structure

Données Clés

Formule: C21H23F3O5S
Synonymes: 1

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.